In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...

Boston Scientific stock pulled back from its run at a record high on Wednesday despite reporting a sweeping third-quarter beat.

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the ...